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Background: Some patients with systemic juvenile idio-
pathic arthritis (sJIA) experience a severe disease course
with destructive arthritis which is refractory to conventional
therapy including the “biologics,” and/or develop life
threatening complications such as macrophage activation
syndrome (MAS). This group of patients has been considered
for allogeneic hematopoietic stem cell transplantation
(HSCT). The aim of this study was to examine the outcome of
patients undergoing allogeneic HSCT for sJIA.
Methods: 8 patients (4 female) with sJIA underwent allo-
geneic HSCT at 3 UK transplant centers between 2007 and
2014. All patients were refractory to standard therapy (n¼4),
had failed autologous HSCT (n¼1), or developed secondary
HLH/MAS poorly responsive to treatment (n¼3). Median age
at transplant was 8.9 years (range 2 - 16 years). All received
reduced toxicity conditioning regimens: Fludarabine,
Melphalan, Alemtuzumab (n¼6) or Treosulfan, Fludarabine,Figure 1.Alemtuzumab (n¼2). All patients received peripheral blood
stem cell grafts: from a 10/10 HLA matched unrelated donor
(n¼5), 9/10 HLA mismatched unrelated donors (n¼2) and
matched sibling (n¼1). Patients received Cyclosporin (CsA)
and mycophenolate mofetil (MMF) for graft-vs-host disease
(GVHD) prophylaxis (n¼5), CsA alone (n¼2) and 1 patient
received Sirolimus and MMF due to previous CsA toxicity.
Results: Seven out of 8 patients are alive with median follow-
up of 16months (range 4 - 56months); one patient who had a
previous unsuccessful autologous HSCT died of severe meta-
bolic acidosis and hyperglycaemia following an orthopedic
procedure 20 months post successful mismatched unrelated
donorHSCT. Four patients achieved full donor chimerism in all
cell lineages and 4 (including both those who received Treo-
sulfan-based conditioning) achieved high levels of mixed
donor chimerism in all lineages. One patient had grade II and 1
patient had grade IV acute GVHD. With the use of Alemtu-
zumab in already heavily immunosuppressed patients, viral
reactivation was observed in most, some with a more severe
disease course (BK encephalitis; HHV6 enterocolitis). All pa-
tients had signiﬁcant improvement of arthritis (Fig 1),
reduction of ESR (Fig 2), resolution of MAS and improved
quality of life following allogeneic HSCT; all achieved
complete drug-free remission of JIA at last follow-up.
Conclusion: Allogeneic HSCT using Alemtuzumab and
reduced toxicity conditioning appears to be an effective
therapeutic option for patients with systemic onset JIAwhich
is refractory to conventional therapy and/or complicated by
MAS. Long term follow up is required to ascertain whether
disease control continues indeﬁnitely.26
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Mixed hematopoietic chimerism is a promising approach to
achieving transplantation tolerance. Transient mixed hemato-
poietic chimerism leads to renal allograft tolerance inabout70%
of cynomolgus monkeys when the kidney is co-transplanted
with MHC-mismatched bone marrow (BMT). This same
approach failed to achieve tolerance with more immunogenic
organs such as lungs and hearts. Murine studies have demon-
strated that the addition of regulatory T cells (Tregs) to BMTs
using a non-myeloablative protocol (that is insufﬁcient to allow
engraftment), permits lasting mixed chimerism, BM engraft-
ment and skin graft tolerance. We aim to extend this approach
into the pre-clinical cynomolgus monkey model.
We have developed a protocol for the expansion of (100
million-1 billion) host polyclonal cynomolgusmacaque Tregs
(pTregs) (CD4+, CD25hi, CD127-/lo, FoxP3+). Cryopreserved
Tregs are thawed andwashed prior to infusion on days 0, 2, 5,
7 and (+/-) 50 to recipients conditioned with total body
irradiation (1.25-1.5cGy) on days -6 and -5, thymic irradia-
tion (7Gy) on day -1, ATGAM on days -2, -1 and 0, anti-CD40L
on days 0, 2, 5, 7, 9 and 12 and cyclosporine or rapamycin
(monotherapy) for 30 days (from day -2 to day 28 after BMT).
To assess for tolerance, a skin or kidney allograft from the
same donor was grafted four months post-BMT, after
discontinuation of all immunosuppression.
Control animals (which did not receive Tregs (n¼4) lost
chimerism within 40 days. In vitro, anti-donor proliferative
responses were observed, and donor kidneys were rejected.
In contrast, animals that received Tregs together with BMT (n
¼ 2) developed remarkably high and long-lasting chimerism,
with a peak of>90% inmyeloid lineages and range of 110-335
days. Unfortunately, experimental animals that reactivated
CMV early after BMTeither succumbed to CMV viremia or lost
the BM graft when treated with myelotoxic antivirals. The
substitution of rapamycin for CyA allowed control of early
CMV reactivation (n¼3 animals) and boosted the number of
Tregs in the peripheral blood. T cell chimerism was observed
only in Treg recipients, with high CD31 expression, suggest-
ing new thymic emigrants. Tregs animals were donor-hypo-
responsive 7 weeks post-BMT. One animal received a kidney
graft on day +120 which was accepted without immuno-
suppression until euthanasia on day 335 (without evidence
for histopathological rejection and with normal kidney
function). The second Treg recipient received skin grafts on
day 119. The third party graft is suspected to be rejected
(histopathology to be conﬁrmed)within 7 days and the donor
skin is visually healthy three weeks post-transplant.
In summary, host pTregs given at the time of BMT across
MHC barriers prolongs donor chimerism up to 335 days
(extending it beyond 60 days for the ﬁrst time in 20 years
using this protocol) without GVHD and allows for the sur-
vival of donor organs transplanted four months post-BMT.Figure 1. Longitudinal physical and mental health status of older and younger
adult related PBSC donors.27
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It is critical to understand HRQoL among older related sib-
lings who are increasingly asked to donate HSC. Findings
presented here are from a 5 year study of related donor (RD)
safety and HRQoL (RDSafe). The goal was to compare HRQoL
in older vs. younger adult RD.
Participants were older adult RD (ages >60 yrs; median¼65
yrs; n¼105) and younger adult RD (ages 18-60; median¼42
yrs; n¼59) who donated PBSC at domestic U.S. centers be-
tween 3/2010 and 4/2013. Data were collected via structured
telephone interviews at pre-donation, and 4 weeks and 1 year
post-donation. Interviews focused on socio-demographics,
physical and mental health, and donation-related perceptions
using well-validated instruments including the SF-12v2 to
assess general physical/mental health. Odds ratios for dichot-
omous variables t-tests for continuous variables and mixed
linear models were used to examine age group differences.
Demographics: Older RDwere less likely to be employed, and
more likely be white, married, and to have children. Pre-
donation: Pre-donation, older RD had poorer physical health
(t¼-3.28; p<.01) but did not differ from younger RD on psy-
chosocial variables including general mental health, depres-
sion, and anxiety. There were no group differences in
ambivalence, satisfaction, or medical concerns about donation
although older RD were more likely to consult their physician
about donation (OR¼13.18; p<.001). Older RD had fewer
work/family concerns (t¼-2.04; p<.05). Post-donation: 4
weeks post-donation, there were no group differences in
general physical health, mental health, or any of 12 donation-
related symptoms. Older RD were less likely to report dona-
tion-related pain (t¼-2.29; p<.05) and continued to have
fewer work/family concerns about the donation process
(t¼-3.39; p<.01). At 1 year post-donation, there were no dif-
ferences in general physical and mental health or in the
percent of RD reporting feeling completely back to normal.
There was a nonsigniﬁcant trend for older RD to report a
longer recovery period (t¼1.78; p¼.08). Older RD reported
fewer current problems sleeping (OR¼0.39; p<.05) but did not
differ from younger RD on any other symptoms or in concern
about longer-term donation effects. Mixed linear models
(Figure 1) indicated that older RD had poorer physical health
